This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lawson, C. R Articles by MacGregor, G. A Search for Related Content PubMed PubMed Citation Articles by Lawson, C. R Articles by MacGregor, G. A Pubmed/NCBI databases Genetics Home Reference Social Bookmarking                         What's this?

Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease

Blood Pressure Unit, Dept of Cardiac & Vascular Sciences, St. George's, University of London, London, UK

Timothy W Doulton

Blood Pressure Unit, Dept of Cardiac & Vascular Sciences, St. George's, University of London, London, UK

Graham A MacGregor

Blood Pressure Unit, Dept of Cardiac & Vascular Sciences, St. George's, University of London, London, UK, gmacgreg{at}sgul.ac.uk

Raised blood pressure (BP) is extremely common in individuals with autosomal dominant polycystic kidney disease (ADPKD) and is almost invariably raised once they develop renal failure. The underlying mechanisms for the rise in BP in individuals with ADPKD are unclear. The progressive number and enlargement of renal cysts, causing structural damage to the kidneys and, thereby, affecting tubular function as well as causing distortion of the glomeruli and renal ischaemia, is likely to be of primary importance.There is some evidence from animal models that there may be over-activity of the intra-renal renin-angiotensin system (RAS) that could account for the rise in BP. Studies in man have shown conflicting results, but a recent more carefully controlled study using both measurements of activity and pharmacological blockade of the RAS clearly demonstrated no evidence of over-activity of the circulating RAS in ADPKD compared to matched individuals with essential hypertension. A more likely explanation for the rise in BP that occurs in ADPKD is retention of sodium and water due to tubular damage. Disappointingly, in spite of good evidence that RAS blocking drugs slow the progression of other renal, particularly glomerular, diseases, there is little evidence to suggest this is true for patients with ADPKD. Nevertheless, there is no doubt that lowering BP in ADPKD is just as important, if not more important, as in essential hypertension to prevent cardiovascular disease and strokes, with a recommended BP target of < 120/80 mmHg.

Key Words: Autosomal dominant polycystic kidney disease • Blood pressure • Renin-angiotensin system • Sodium • ACE inhibitor

References

• Ansell D., Feest T., Ahmad A., Rao R. UK Renal Registry: 7th Annual Report: UK Renal Registry, 2004.
• Somlo S., Saggar-Malik AK Autosomal dominant polycystic kidney disease. In: Flinter F, Maher E, Saggar-Malik AK, editors. The Genetics of Renal Disease. Oxford, 2003:204-27.
• Igarashi P., Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002;13:2384-98.[Free Full Text]
• Ong AC, Harris PC Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005;67:1234-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wilson P. Polycystic kidney disease. N Engl J Med 2004;350:151-64.[Free Full Text]
• Peters DJ, Spruit L., Saris JJ et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993;5:359-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hateboer N., van Dijk MA, Bogdanova N. et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999;353:103-07.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chapman AB, Gabow PA Hypertension in autosomal dominant polycystic kidney disease. Kidney Int Suppl 1997;61:S71-S73.[Medline] [Order article via Infotrieve]
• Calabrese G., Vagelli G., Cristofano C., Barsotti G. Behaviour of arterial pressure in different stages of polycystic kidney disease. Nephron 1982;32:207-08.[Web of Science][Medline] [Order article via Infotrieve]
• Gabow PA, Ikle DW, Holmes JH Polycystic kidney disease: prospective analysis of nonazotemic patients and their family members. Ann Intern Med 1984;101:238-47.[Abstract/Free Full Text]
• Gabow PA Autosomal dominant polycystic kidney disease - more than just a renal disease. Am J Kidney Dis 1990;16:403-13.[Web of Science][Medline] [Order article via Infotrieve]
• Hansson L., Karlander LE, Lundgren W., Peterson LE Hypertension in polycystic kidney disease. Scand J Urol Nephrol 1974;8:203-05.[Web of Science][Medline] [Order article via Infotrieve]
• Milutinovic J., Fialkow PJ, Agodoa LY, Phillips LA, Rudd TG, Sutherland S. Clinical manifestations of autosomal dominant polycystic kidney disease in patients older than 50 years. Am J Kidney Dis 1990;15:237-43.[Web of Science][Medline] [Order article via Infotrieve]
• Gabow PA, Johnson AM, Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-19.[Web of Science][Medline] [Order article via Infotrieve]
• Fick GM, Johnson AM, Hammond WS, Gabow PA Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048-56.[Abstract]
• Franz KA, Reubi FC Rate of functional deterioration in polycystic kidney disease. Kidney Int 1983;23:526-9.[Web of Science][Medline] [Order article via Infotrieve]
• Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002;39:1127-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gabow PA, Chapman AB, Johnson AM et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-80.[Web of Science][Medline] [Order article via Infotrieve]
• Gabow PA, Heard E., Pertorius D. et al. Relationship between renal structure and hypertension in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int 1995;31:297.
• Ritter SA, Baehr G. The arterial supply of the congenital polycystic kidney and its relation to the clinical picture. J Urol 1929;21:583-92.[Web of Science]
• Ettinger A., Kahn PC, Wise HMJ. The importance of selective renal angiography in the diagnosis of polycystic disease. J Urol 1969;102:156-61.[Web of Science][Medline] [Order article via Infotrieve]
• Nash DAJ. Hypertension in polycystic kidney disease without renal failure. Arch Int Med 1977;137:1571-5.[Abstract/Free Full Text]
• Valvo E., Gammaro L., Tessitore N. et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations. Am J Nephrol 1985;5:176-81.[Web of Science][Medline] [Order article via Infotrieve]
• Torres VE, Wilson DM, Burnett JC, Johnson CM, Offord KP Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991;66:1010-17.[Web of Science][Medline] [Order article via Infotrieve]
• Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1988;34:683-90.[Web of Science][Medline] [Order article via Infotrieve]
• Ramunni A., Saracino A., Esposito T., Saliani MT, Coratelli P. Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease. Hypertens Res 2004;27:221-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chapman AB, Johnson A., Gabow PA, Schrier RW The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-6.[Abstract]
• Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA Sodium restriction lowers high blood pressure through a decreased response of the renin system - direct evidence using saralasin. J Hypertens 1985;3:243-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ The renin-angiotensin-aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects. Clin Sci 1980;59:95s-99s.[Medline] [Order article via Infotrieve]
• Sagnella GA Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001;15:17-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Doulton TWR, Saggar-Malik AK, He FJ et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006;24(5):939-45.[Web of Science][Medline] [Order article via Infotrieve]
• Martinez-Vea A., Valero FA, Bardaji A. et al. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 2000;20:193-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Watson ML, MacNicol AM, Allan PL, Wright AF Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 1992;41:206-10.[Web of Science][Medline] [Order article via Infotrieve]
• Barrett BJ, Foley R., Morgan J., Hefferton D., Parfrey P. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118-23.[Web of Science][Medline] [Order article via Infotrieve]
• Harrap SB, Davies DL, Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-08.[Web of Science][Medline] [Order article via Infotrieve]
• Graham PC, Lindop GBM. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988;33:1084-90.[Web of Science][Medline] [Order article via Infotrieve]
• Torres VE, Donovan KA, Scicli G. et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 1992;42:364-73.[Web of Science][Medline] [Order article via Infotrieve]
• Loghman-Adham M., Soto C., Inagami T., Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004;287:F775-F788.[Abstract/Free Full Text]
• McPherson EA, Luo Z., Brown RA et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2004;15:493-500.[Abstract/Free Full Text]
• Lavoie JL, Lake-Bruse KD, Sigmund CD Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol 2004;286:F965-F971.[Abstract/Free Full Text]
• Crowley SD, Gurley SB, Oliverio MI et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 2005;115(4):1092-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de Leeuw PW, Birkenhager WH The renal circulation in essential hypertension. J Hypertens 1983;1:321-31.[CrossRef][Medline] [Order article via Infotrieve]
• Lightenberg G., Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-8.[Abstract/Free Full Text]
• Tuncel M., Augustyniak R., Zhang W., Toto RD, Victor RG Sympathetic nervous system function in renal hypertension. Curr Hypertens Reports 2002;4:229-36.[Web of Science][Medline] [Order article via Infotrieve]
• Neumann J., Ligtenberg G., Klein II, Koomans HA, Blankestijn PJ Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance and treatment. Kidney Int 2004;65:1568-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Klein Ihht, Ligtenberg G., Oey PL, Koomans HA, Blankestijn PJ Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33.[Abstract/Free Full Text]
• Wang D., Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 1997;15:925-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schmid M., Mann JF, Stein G. et al. Natriuresis-pressure relationship in polycystic kidney disease. J Hypertens 1990;8:277-83.[Web of Science][Medline] [Order article via Infotrieve]
• Torres VE, Wilson DM, Offord KP, Burnett JC, Romero JC Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin Proc 1989;64:509-15.[Web of Science][Medline] [Order article via Infotrieve]
• Danielsen H., Pedersen EB, Nielsen AH, Herlevsen P., Kornerup HJ, Posborg V. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 1986;219:399-405.[Web of Science][Medline] [Order article via Infotrieve]
• Zabka J., Tesar V., Merta M. Hypertension in patients with polycystic kidney disease [abstract]. Sbornik Lebarsky 1991;93:325-38.
• Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41.[Abstract/Free Full Text]
• Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, Group ftCS. The effect of angiotensin-converting enzyme inhbition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy in type 2 diabetes. N Engl J Med 2001;45:851-60.
• Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.[Abstract/Free Full Text]
• Ecder T., Edelstein CL, Fick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001;21:98-103.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schrier RW, McFann K., Johnson A. et al. Cardiac and renal effects of standard versus rigourous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733-9.[Abstract/Free Full Text]
• van Dijk MA, Breuning MH, Duiser R., vas Es LA, Westendorp RGJ. No effect of enalapril on progression in ADPKD. Nephrol Dial Transplant 2003;18:2314-20.[Abstract/Free Full Text]
• Jafar TH, Stark PC, Schmid CH et al. The effect of angiotensin-converting enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005;67:265-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Florijn KW, Chang PC, van der Woude FJ, van Bockel J., van Saase JL Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation. Transplantation 1994;57(1):73-81.[Medline] [Order article via Infotrieve]
• De Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol 2003;14:2421-7.[Abstract/Free Full Text]
• Kannel WB Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991;9(2):S3-S8.
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.[Abstract/Free Full Text]
• Chapman AB, Johnson AM, Rainguet S., Hossack KF, Gabow PA, Schrier RW Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-7.[Abstract]
• Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Gabow PA Cardiovascular abnormalities in children with autosomal dominant polycystickidney disease. J Am Soc Nephrol 1995;5:2032-6.[Abstract]
• Valero FA,Martinez-Vea A., Bardaji A. et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020-6.[Abstract/Free Full Text]
• Saggar-Malik AK, Missouris CG, Gill JS, Singer DRJ, Markandu ND, MacGregor GA Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. Br Med J 1994;309:1617-18.[Free Full Text]
• Zeier M., Geberth S., Schmidt KG, Mandelbaum A., Ritz E. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3:1451-7.[Abstract]
• Ecder T., Edelstein CL, Chapman A. et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999;14:1113-16.[Abstract/Free Full Text]
• Tao Y., Kim J., Schrier RW, Edelstein CL Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.[Abstract/Free Full Text]
• Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006;103:5466-71.[Abstract/Free Full Text]
• Mangoo-Karim R., Uchic ME, Grant M. et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB Journal 1989;3:2629-32.[Abstract]
• Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant 2006;21:1752-7.[Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 3, 139-145 (2006)
DOI: 10.3317/jraas.2006.023


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lawson, C. R Articles by MacGregor, G. A Search for Related Content PubMed PubMed Citation Articles by Lawson, C. R Articles by MacGregor, G. A Pubmed/NCBI databases Genetics Home Reference Social Bookmarking                         What's this?